DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · IEX Real-Time Price · USD
2.370
+0.050 (2.16%)
Jun 20, 2024, 3:32 PM EDT - Market open

DiaMedica Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 2016
Selling, General & Admin
8.166.164.884.493.69
Upgrade
Research & Development
13.117.848.778.217.9
Upgrade
Operating Expenses
21.271413.6512.711.59
Upgrade
Operating Income
-21.27-14-13.65-12.7-11.59
Upgrade
Other Expense / Income
-2.01-0.33-0.03-0.43-0.98
Upgrade
Pretax Income
-19.26-13.67-13.61-12.27-10.62
Upgrade
Income Tax
0.040.030.030.030.03
Upgrade
Net Income
-19.3-13.7-13.64-12.3-10.65
Upgrade
Shares Outstanding (Basic)
3326211612
Upgrade
Shares Outstanding (Diluted)
3326211612
Upgrade
Shares Change
23.16%27.29%32.48%30.80%54.81%
Upgrade
EPS (Basic)
-0.60-0.52-0.65-0.78-0.89
Upgrade
EPS (Diluted)
-0.60-0.52-0.65-0.78-0.89
Upgrade
Free Cash Flow
-18.75-11.59-12.27-9.22-9.09
Upgrade
Free Cash Flow Per Share
-0.58-0.44-0.59-0.59-0.76
Upgrade
EBITDA
-19.16-13.58-13.53-12.2-10.55
Upgrade
Depreciation & Amortization
0.10.090.080.070.07
Upgrade
EBIT
-19.26-13.67-13.61-12.27-10.62
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).